Health
More Than 40 American Oncology Network Clinics Across 18 States and Washington, D.C., Now Offering Bispecific T-cell Engager Therapies to Patients
AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancersFORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, is now offering Bispecific T-cell Engager (BiTE) therapy—also known as BiTE therapy—at more than 40 partner practice clinics in 18 states and Washington, D.C. This advancement brings cutting-edge
About this update from Aon Plc
[{"type":"image","alt":"American Oncology Network","displaySize":"","headline":null,"caption":"American Oncology Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/4951e556d9ba9a3b499222e1d75dc487"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xYGUeeQaq6O8UVUpyYHeyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4951e556d9ba9a3b499222e1d75dc487","width":300,"height":109}},"lazy":false},{"type":"text","content":"AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancers","length":142,"tagName":"p"},{"type":"text","content":"FORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, is now offering Bispecific T-cell Engager (BiTE) therapy—also known as BiTE therapy—at more than 40 partner practice clinics in 18 states and Washington, D.C. This advancement brings cutting-edge cancer treatment directly to patients in community settings, expanding access to a promising class of immunotherapies that may offer new hope for those with cancers resistant to standard treatments.","length":572,"tagName":"p"},{"type":"image","alt":"13436_AON_Schonherz-Divers-Chang_Press-Release_Headshot_250721 (1)","displaySize":"","headline":null,"caption":"13436_AON_Schonherz-Divers-Chang_Press-Release_Headshot_250721 (1)","className":"","disableSlideshowImg":false,"size":{"original":{"width":750,"height":365,"url":"https://media.zenfs.com/en/globenewswire.com/4f2946bd2fdbcdb0e035bcf08fe1e9b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TcVlqPnguY27MtD7Y_ea7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4f2946bd2fdbcdb0e035bcf08fe1e9b7","width":750,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/equ6STymiJ7ljugMNuLWlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/4f2946bd2fdbcdb0e035bcf08fe1e9b7","width":750,"height":365}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Bispecific therapies represent a major breakthrough in cancer care. These innovative therapies engage...